Sintx Technologies is trying to turn a decades-old silicon nitride franchise into a commercial ceramics and implant platform before liquidity runs out. The June quarter is the first print in which OEM industrial demand and the first SiNAPTIC foot-and-ankle wedge sales show up together. That is progress, not proof. Product sales jumped and gross margin widened, yet the operating loss still dwarfs the revenue base. Management rebuilt stockholders' equity with a June unit financing and later regained the Nasdaq Capital Market minimum-equity standard. The same raise stacked immediately exercisable warrants against a share price that still sits below the strike.
The tension is conversion versus cash. In June the company announced industrial purchase orders above $3 million from existing contract-manufacturing customers. Production on those orders is already under way. Second-half guidance implies a step-up that would more than double the first-half run-rate if shipments and customer acceptance land on schedule. Cash at mid-year was only $3.6 million. That cash figure follows a first-half operating outflow of $5.3 million. Inventory more than doubled as the Salt Lake City plant staged work for those orders. The order book is real demand. It is also a working-capital claim that consumes cash before revenue is recognized.
The counterargument is already in the filing language. Substantial doubt about going concern remains even after the raise. The SiNAPTIC system has a first-in-human case and a limited-use launch, not a repeatable hospital channel. The next two quarters resolve whether OEM shipments convert into recognized sales near the guided range and whether the wedge system produces more than a token medical contribution. If both stall, the remaining at-the-market capacity and the warrant stack become the financing path rather than a backstop. The equity is a conversion story priced as if the platform option is still alive. The cash clock is what decides whether that option expires.